A

Alexion

Global biopharmaceuticals focusing on rare diseases

Regional Account Manager - Rare Neurology

Full-TimeUpdated on 10/23/2026Deadline 11/3/26
$152.6k - $229k/yr+ Short-term incentive bonuses + Equity-based awards + Sales commissions
Senior
Bachelor's, Master's, MBA
Toledo, OH, USA+1 moreMore locations: Columbus, OH, USA
In PersonField-based role with regular territory travel, including frequent overnight and weekend travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • A proven, documented track record of delivering consistent top-tier sales results is required.
  • Five years of pharmaceutical sales experience or equivalent experience in biotech or medical devices is required.
  • A valid driver's license and clean driving record are required.
  • The role requires regular travel within the territory, including frequent overnight and weekend travel.
  • The role requires the ability to travel by public transportation, automobile, train, or plane; work comfortably in a clinical setting; use a computer; communicate by phone, video, and electronic messaging; problem-solve; engage in complex and non-linear thought, analysis, and dialogue; collaborate with others; and generally be available during standard business hours.
Responsibilities
  • Manage and develop long-term relationships with assigned physicians, extended prescribers, and other customers in the assigned territory.
  • Represent assigned Alexion brands and their approved indications, and provide disease and product education to external customers, including physicians and nurses, to help patients.
  • Consistently achieve or exceed sales objectives in the assigned territory while following organizational ethics and compliant business practices.
  • Create, maintain, and execute strategic account-specific business plans that reflect the brand plan and an in-depth understanding of local market forces.
  • Collaborate with institutional account managers, TLLs, SALs, MSLs, FRMs, Market Access, Diagnostics, and other enterprise partners.
  • Handle customer questions and objections consistently with product indications and sales training methodology, and compliantly triage inquiries to appropriate partners.
  • Develop and maintain in-depth clinical and scientific knowledge of diseases and therapeutics.
  • Educate customers on disease diagnostic approaches that support effective patient diagnosis.
  • Navigate complex academic and community hospital settings to access targeted healthcare professionals and other key stakeholders.
  • Use marketing tools and resources, including PowerPoint presentations, to further the selling process across customer stakeholders.
  • Lead implementation of a patient-centric partnership model involving physicians, their staff, clinics, and applicable hospitals.
  • Execute local disease education and promotional programs for the therapeutic area.
  • Provide product expertise and customer service to targeted accounts and appropriate stakeholders.
  • Accurately and promptly track activities and submit sales activity reports.
  • Manage the territory budget and adhere to Alexion's code of ethics and compliance.
Desired Qualifications
  • Neurology experience is strongly preferred, particularly building relationships with physicians who refer, diagnose, or treat neuromuscular disorders in high-complexity institutions, community hospitals, satellite sites, and private practices.
  • Where appropriate, experience building relationships with healthcare professionals at locations administering infused therapies or apheresis for immunological disorders is preferred.
  • Demonstrated success educating physicians about complex diseases diagnosed mainly through observation or exclusion rather than simple diagnostic tests is preferred.
  • Experience educating physicians about diverse patient disease profiles that do not lend themselves to simple segmentation and categorization for treatment decisions is preferred.
  • Ability to build or strengthen lasting relationships with providers in physician practices and hospitals where access may be challenging is preferred.
  • A master's degree in life sciences or an MBA is a plus.
  • Bio/pharma, neurology, or ophthalmology experience is preferred.
  • Experience navigating and working with large hospital systems, integrated delivery networks, and academic teaching hospitals is preferred.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old